- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Becton, Dickinson and Company Appoints Greg Rodetis as Senior Vice President of Investor Relations
Rodetis will also continue to serve as the company's treasurer.
Global medical technology company Becton, Dickinson and Company (BD) announced that it has appointed Gred Rodetis as senior vice president of investor relations.
Rodetis will also continue to serve in his role as treasurer.
In a press release, BD chief financial officer and executive vice president Chris DelOrefice said, “Greg's deep knowledge of BD, coupled with his expertise of the capital markets and existing relationships with the investment banking community, make him well-positioned to lead our investor relations function and serve as a valued partner to this important stakeholder group as BD continues to deliver on its growth strategy.”
SOURCE
(October 17, 2023); BD (Bection, Dickinson and Company); BD Names Greg Rodetis as Senior Vice President of Investor Relations; https://www.prnewswire.com/news-releases/bd-names-greg-rodetis-as-senior-vice-president-of-investor-relations-301958983.html
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
